Changing the receptor specificity of anthrax toxin

mBio

Volumn 3, Issue 3, 2012, Pages

  Mechaly, Adva ^a,b   McCluskey, Andrew J ^a   John Collier, R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX TOXIN RECEPTOR 1; ANTHRAX TOXIN RECEPTOR 2; ANTIGEN; EDEMA FACTOR ENZYME; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; LETHAL FACTOR ENZYME; MUTATED PROTECTIVE ANTIGEN CARBOXY TERMINAL DIPHTHERIA TOXIN FUSION PROTEIN; MUTATED PROTECTIVE ANTIGEN CARBOXY TERMINAL EPIDERMAL GROWTH FACTOR FUSION PROTEIN; PROTECTIVE ANTIGEN; RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY TEST; ESCHERICHIA COLI; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; RECEPTOR BINDING;

BACTERIA (MICROORGANISMS);

EID: 84863449301     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00088-12     Document Type: Article

References (37)

1. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. 2007. Immunotoxin treatment of cancer. Annu. Rev. Med. 58:221-237.
2. Young JAT, Collier RJ. 2007. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76: 243-265.
3. Duesbery NS, et al. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
4. Leppla SH. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A. 79:3162-3166.
5. Vitale G, et al. 1998. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248:706-711.
6. Miller CJ, Elliott JL, Collier RJ. 1999. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 38:10432-10441.
7. Collier RJ. 2009. Membrane translocation by anthrax toxin. Mol. Aspects Med. 30:413-422.
8. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414: 225-229.
9. Scobie HM, Rainey GJ, Bradley KA, Young JA. 2003. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 100:5170-5174.
10. Klimpel KR, Molloy SS, Thomas G, Leppla SH. 1992. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. U. S. A. 89:10277-10281.
11. Milne JC, Furlong D, Hanna PC, Wall JS, Collier RJ. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:20607-20612.
12. Kintzer AF, et al. 2009. The protective antigen component of anthrax toxin forms functional octameric complexes. J. Mol. Biol. 392:614-629.
13. Cunningham K, Lacy DB, Mogridge J, Collier RJ. 2002. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc. Natl. Acad. Sci. U. S. A. 99:7049-7053.
14. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ. 2002. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc. Natl. Acad. Sci. U. S. A. 99:7045-7048.
15. Lacy DB, Wigelsworth DJ, Melnyk RA, Harrison SC, Collier RJ. 2004. Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc. Natl. Acad. Sci. U. S. A. 101:13147-13151.
16. Scobie HM, et al. 2005. A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J. Infect. Dis. 192:1047-1051.
17. Wigelsworth DJ, et al. 2004. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen. J. Biol. Chem. 279:23349-23356.
18. Rosovitz MJ, et al. 2003. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 278:30936-30944.
19. Collier RJ. 1967. Effect of diphtheria toxin on protein synthesis: inactivation of one of the transfer factors. J. Mol. Biol. 25:83-98.
20. Collier RJ, Cole HA. 1969. Diphtheria toxin subunit active in vitro. Science 164:1179-1181.
21. Lin CR, et al. 1984. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messengerRNAproducts in A431 cells. Science 224:843-848.
22. Ullrich A, et al. 1984. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-425.
23. Krantz BA, et al. 2005. A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore. Science 309:777-781.
24. Arora N, Klimpel KR, Singh Y, Leppla SH. 1992. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J. Biol. Chem. 267:15542-15548.
25. Arora N, Leppla SH. 1994. Fusions of anthrax toxin lethal factor with Shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect. Immun. 62:4955-4961.
26. Hu H, Leppla SH. 2009. Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein. PLoS One 4:e7946.
27. Milne JC, Blanke SR, Hanna PC, Collier RJ. 1995. Protective antigenbinding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol. Microbiol. 15:661-666.
28. Pentelute BL, Barker AP, Janowiak BE, Kent SBH, Collier RJ. 2010. A semisynthesis platform for investigating structure-function relationships in the N-terminal domain of the anthrax lethal factor. ACS Chem. Biol. 5:359-364.
29. Pentelute BL, Sharma O, Collier RJ. 2011. Chemical dissection of protein translocation through the anthrax toxin pore. Angew. Chem. Int. Ed. Engl. 50:2294-2296.
30. Wesche J, Elliott JL, Falnes PØ, Olsnes S, Collier RJ. 1998. Characterization of membrane translocation by anthrax protective antigen. Biochemistry 37:15737-15746.
31. Abi-Habib RJ, et al. 2006. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol. Cancer Ther. 5:2556-2562.
32. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. 2000. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res. 60:6061-6067.
33. Louie GV, Yang W, Bowman ME, Choe S. 1997. Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor. Mol. Cell 1:67-78.
34. Krantz BA, Finkelstein A, Collier RJ. 2006. Protein translocation through the anthrax toxin transmembrane pore is driven by a proton gradient. J. Mol. Biol. 355:968-979.
35. Katayama H, et al. 2010. Three-dimensional structure of the anthrax toxin pore inserted into lipid nanodiscs and lipid vesicles. Proc. Natl. Acad. Sci. U. S. A. 107:3453-3457.
36. Ciardiello F, Tortora G. 2008. EGFR antagonists in cancer treatment. N. Engl J. Med. 358:1160-1174.
37. Hu H, Leppla SH. 2009. Anthrax toxin uptake by primary immune cells as determined with a lethal factor-β-lactamase fusion protein. PLoS One 4:e7946.